

## CURRICULUM VITAE

PETER CHRISTIAN ALBERTSEN  
University of Connecticut Health Center  
Division of Urology  
Farmington, Connecticut 06030-3955  
P: 860-679-3676  
F: 860-679-1318  
E: albertsen@nso.uchc.edu

Education:	Princeton University, B.A., Biochemistry, <u>cum laude</u>	1974
	Columbia University, M.D.	1978
	University of Wisconsin, M.S., Medical Administration and Preventive Medicine	1990
Residency:	Fifth (Harvard) Surgical Service	1978-1980
	New England Deaconess Hospital	Boston, MA
	Brady Urological Institute	1980-1984
	Johns Hopkins Hospital	Baltimore, MD
Employment:	Instructor Brady Urological Institute	1985-1986
	Private Practice	Baltimore, MD
	University of Connecticut Health Center	Farmington, CT
	Assistant Professor	1987-1994
	Associate Professor	1994-2000
	Professor	2000-present
	Division Chief and Residency Program Director	1995-present
	Associate Dean for Clinical Research Planning & Administration	2006-present
Awards:	Sigma Xi, Princeton Chapter	1974
	P & S Alumni Association Bronze Medal	1978
	American Urological Association, First Prize Essay	1983
	American Society of Andrology, First Prize Essay	1984
	Board of Directors Faculty Recognition Award	2005
	America's Top Doctors	2009, 2010, 2011
Licensed:	Connecticut	1987
Certified:	American Board of Urology	1986
	Recertified	1994, 2004
National & Regional Appointments:		
	Trustee - American Board of Urology	2001-2007
	President - American Association of Clinical Urologists	2005-2006
	President - New England Section of the American Urological Association	2004-2005
	President - Society of University Urologists	2008-2009
	Residency Review Committee - ACGME for Urology	2003-2009
	Chairman, Cause of Death Committee - National Cancer Institute PLCO Screening Trial,	1999-present
	New England Section Representative - American Association Clinical Urologists	1998-2004
	Connecticut Representative - New England Section of the American Urological Association	1997-1999
	Historian - New England Section American Urological Association	2002-2004
	National Blue Cross/Blue Shield Technology Assessment Panel	1997-present

NIH Study Section (Epidemiology and Disease Control – 2)	1996-1998
Committee on Third Party Payers - Hartford County Medical Association	1989-1995
Board Member - Hartford County Medical Society	1994-2000
President - Hartford County Medical Association	1998-1999
Vice President - Hartford County Medical Association	1997-1998
Secretary/Treasurer - Hartford County Medical Association	1996-1997
Socio-economic Consultant - BPH guidelines panel of the Agency for Healthcare Research & Quality	1990-1993
Socio-economic Representative (New England Section) - American Urological Association	1989-2002
Board Chairman - Health Management Corporation, a subsidiary of ConnectiCare, Inc.	1994-1999
Board Member - Health Management Corporation, a subsidiary of ConnectiCare, Inc.	1991-1994
Board Member - Drug Utilization Review, State of Connecticut Department of Income Maintenance	1991-1995

Editorial Boards:

Urology	1993-present
Urology Times	1993-present
Journal of Urology – Urological Survey	2000-2006
Urologic Oncology	2001-2006

Reviewer:

Cancer	1995-present
Investigative Urology	2000-present
JAMA	1994-present
Journal of the National Cancer Institute	1994-present
Journal of Urology	1994-present
New England Journal of Medicine	1997-present
Urology	1994-present

Institutional Appointments:

Medical Director, Operating Room, John Dempsey Hospital	1990-1991
Chairman, Operating Room Committee	1990-1991
Associate Dean, Continuing Medical Education	1991-1994
Chairman, Ambulatory Operations Committee, University Physicians	1991-1993
Chairman, Managed Health Care Committee, University Physicians	1992-1993
Interim Medical Director, University Physicians	1993-1996
Clinical Governance Committee	1997-2006
Chairman, Finance Funds and Flow Committee	1999-2001
Chairman, Strategic Planning Committee	2002-2006
Compensation Committee	2003-2006
Senior Appointments and Promotions Committee	2004-2006
Associate Dean for Clinical Affairs	2006-2010
Chairman, Clinical Council Finance Subcommittee	2006-present

Research Projects:	Total Award
Evaluation of Atamestane of Benign Prostatic Hyperplasia 6/1/91-12/31/94 Berlex Laboratories	\$20,726
Prostate Cancer : A Retrospective Survival Analysis Year 01 8/1/91-7/30/92 U.S. Public Health Service	\$224,376
A Double Blind Study to Investigate Long-Term Effects of Finasteride 11/20/91-2/28/99 Covance/Merck Research Laboratories	\$129,759
A 16-Week Double-Blind Placebo-Controlled Dose-Titration Study Using Doxazosin Tablets for the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients 12/1/91-11/30/95 Pfizer, Inc	\$26,008
Prostate Cancer : A Retrospective Survival Analysis Year 02 8/1/92-7/30/93 U.S. Public Health Service	\$166,678
Port II for Prostatic Diseases Year 01 9/1/94-8/31/95 National Institutes of Health	\$155,992
Port II for Prostatic Diseases Year 02 9/1/95-1/31/96 National Institutes of Health	\$132,604
Pilot Study on Measurement of Utilities in Prostate Cancer 11/1/95-10/31/96 Dept. of Public Health and Addiction Services	\$143,478
Port II for Prostatic Diseases Year 03 2/1/96-10/31/97 National Institutes of Health	\$28,255
Prostate Cancer Practice Patterns & Quality of Life Phase I 8/1/96-7/31/97 Connecticut Department of Public Health	\$223,040
Prostate Cancer Practice Patterns & Quality of Life Phase II 8/1/97-5/31/98 Connecticut Department of Public Health	\$81,703
Trends in Prostate Cancer Mortality 9/30/97-9/29/98 Connecticut Department of Public Health	\$102,480
Prostate Cancer Practice Patterns & Health Related Quality of Life Phase III 9/30/97-10/31/98 Connecticut Department of Public Health	\$63,538
Port II for Prostatic Diseases Year 04 11/1/97-10/31/98 National Institutes of Health	\$36,110
Mechanisms of Chronic Prostatitis Year 01 7/7/97-5/31/98 National Institutes of Health	\$229,919
Port II for Prostatic Diseases Year 05 10/31/98-8/31/99 National Institutes of Health	\$36,745
Mechanisms of Chronic Prostatitis Year 02 6/1/98-5/31/99 National Institutes of Health	\$236,887
Comparison of Treatment Efficacy for Prostate Cancer 9/1/98-8/31/03 Agency Health Care Policy and Research	\$1,413,757
Prostate Cancer Practice Patterns & Quality of Life Phase IV 11/1/98-6/29/99 Connecticut Department of Public Health	\$34,929
Prostate Cancer Practice Patterns & Quality of Life Phase V 7/1/99-3/31/01 Connecticut Department of Public Health	\$267,195
Prostate Cancer Practice Patterns & Quality of Life Phase VI 1/1/01-6/30/01 Connecticut Department of Public Health	\$19,715
A Study to Determine Minimum Difference for Patients with Benign Prostatic Hyperplasia 10/28/98-10/27/00 Glaxo Welcome	\$14,350
Mechanisms of Chronic Prostatitis Year 03 6/1/99-5/31/00 National Institutes of Health	\$243,259
Intergovernmental Personnel Act – P. Albertsen 12/1/99-3/1/01 Centers for Disease Control & Prevention	\$44,099
Mechanisms of Chronic Prostatitis Year 04 6/1/00-5/31/01 National Institutes of Health	\$249,914

Prostate Cancer Outcomes Study Phase VI 1/1/01-7/31/01 Connecticut Department of Public Health	\$19,715
Prostate Cancer Outcomes Study Phase VII 7/7/01-6/30/02 Connecticut Department of Public Health	\$119,137
Benign Prostatic Hyperplasia Alpha-Adrenergic Antagonist 07/1/01-12/31/03 Pharmaceutical Research Assoc.	\$24,774
Prostate Cancer Outcomes Study Phase VIII 8/15/02-7/31/03 Connecticut Department of Public Health	\$17,299
The Selenium and Vitamin E Chemoprevention Trial (SELECT) 09/1/01- 5/31/13 Southwest Oncology Group	\$149,430
Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 01 9/30/01-9/29/02 Massachusetts General Hospital	\$12,365
Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 02 9/30/02-9/29/03 Massachusetts General Hospital	\$14,952
The Effect of Zometa compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy 3/15/03 – 3/15/05 Novartis Pharmaceutical Corporation	\$3,878
Prostate Cancer Outcomes Study Phase IX 9/30/03-9/29/04 Connecticut Department of Public Health	\$16,885
Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 03 9/30/03-9/29/04 Massachusetts General Hospital	\$10,312
Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 04 9/30/04-3/31/06 Massachusetts General Hospital	\$ 7,095
Development of a Predictive Model for Prostate Cancer Progression 4/18/06-4/17/07 Aureon Laboratories, Inc	\$38,000
Evaluation of Palliative Prostate Cancer among Elderly Men 8/1/06 – 7/31/11 University of Medicine & Dentistry of New Jersey / Robert Wood Johnson Medical School (NCI)	\$43,591
Prostate Tissue Array Project 9/15/06-9/14/11 The V Foundation for Cancer Research	\$50,000
Race, Co-morbidity and Long Term Prostate Cancer Outcomes 8/1/07 – 7/31/10 University of Southern California, Los Angeles (NCI)	\$164,012
A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy 7/2/07 – 9/30/11 Sanofi - Aventis	\$12,400
Evaluation of Circulating Tumor Cell Measurements in Diagnosis of Prostate Cancer 3/3/08-2/24/10 Ikonisys	\$14,259

## PUBLICATIONS

1. **Albertsen PC\*** Histologic Grading and the Practicing Urologist. *The Prostate* 1982; 3:333-338.
2. **Albertsen PC\***, Marshall F, Optimal Management of Prostate Cancer. *Geriatrics* 1982; 37:69-79.
3. **Albertsen PC\***, Chang TSK. Hormone Measurements in the Assessment of Male Infertility. *J Clin Immunoassay* 1983; 6:51-56.
4. **Albertsen PC\***, Chang TSK, Vindivich D, Robinson JC, Smyth JW. A Critical Method of Evaluating Tests for Male Infertility. *J Urol* 1983; 130:467-475.
5. **Albertsen PC\***, Albertsen PS. Evaluation of a New Nonadhesive Urine Collection Device for Patients with Ileal Conduits. *J Urol* 1984; 131:454-455.
6. Chang TSK, **Albertsen PC**. Interpretation and Utilization of the Zona Pellucida-Free Hamster Egg Penetration Test in the Evaluation of the Infertile Male. *Seminars in Urology* 1984; 2:124-130.
7. Brendler CB, **Albertsen PC**, Goldman SM, Hill GS, Lowe FC, Millan JC. Acquired Renal Cystic Disease in the End-Stage Kidney: Urological Implications. *J Urol* 1984; 132:548-552.
8. Nadel SN, Hutchins GM, **Albertsen PC**, White RI. Valves of the Internal Spermatic Vein: Potential for Misdiagnosis of Varicocele by Venography. *Fertility & Sterility* 1984; 41:479-481.
9. Oesterling JE, Bromberg WD, **Albertsen PC\***. Xeroradiography and Ultrasonography in the Evaluation of a Penile Injury. *J Urol* 1986; 135:791-793.
10. Gearhart J, **Albertsen PC**, Jeffs RD. Applications of Augmentation Cystoplasty: The Johns Hopkins Experience. *J Urol* 1986; 136:430-435.
11. **Albertsen PC\***, Kamens EA. Variations in Coding Practices Among Connecticut Urologists for the Medicare Population. *Connecticut Medicine* 1990; 54:508-512.
12. Small JD, **Albertsen PC**, Graydon RJ, Ricci A, and Sardell WV. Adenoid Cystic Carcinoma of Cowper's Gland. *J Urol* 1992; 147:699-701.
13. Fleming C, Wasson J, **Albertsen PC**, Barry M, and the Prostate PORT. A Decision Analysis of Alternative Treatment for Clinically Localized Prostate Cancer. *JAMA* 1993; 269:2650-2658.
14. Wasson J, Fleming C, Bruswitz R, **Albertsen PC**, Barry M, Yad G, Wennberg J, Littenburg B, Mully A. The Treatment of Localized Prostate Cancer: What are We Doing, What Do We Know, and What Should We Be Doing? *Seminars in Urology* 1993; 11:23-26.
15. Cromley EK, **Albertsen PC**. Patterns of Multiple-Site Physician Practices. *Health Services Research* 1993; 28:503-522. PMID: PMC1069954
16. **Albertsen PC\***. Computer Modeling and Decision-Making: Clinical Applications in Bladder Cancer. *Seminars in Urology* 1993; 11:171-176.
17. **Albertsen PC\***, Fine J. Building Population Data Bases: Lessons From a Community Project. *Clinical Performance and Quality Health Care* 1993; 1(4):191-193.
18. Potosky AL, Miller BA, **Albertsen PC**, Kramer BS. The Role of Increasing Detection in the Rising Incidence of Prostate Cancer. *JAMA* 1995; 273:548-552.
19. **Albertsen PC\***, Fine J. Prostate biopsy in the Community. Who are the most likely Candidates? *Contemporary Urology* 1995; 7:54-57.
20. **Albertsen PC\***. A 72-Year Old Man with Localized Prostate Cancer. *JAMA* 1995; 274:69-74.
21. **Albertsen PC\***, Fryback DG, Storer DE, Kolon TF, Fine J. Long-term Survival among Men with Conservatively Treated Localized Prostate Cancer. *JAMA* 1995; 274:626-631.
22. Mulhall JP, **Albertsen PC\***. Hemospermia: Diagnosis and Treatment. *Urology* 1995; 46:463-467.
23. Wasson JH, **Albertsen PC**. Prostate Disease: An Emergency only for the Patient. *Emergency Medicine* 1995; 27:20-40.
24. Gee WF, Holtgrewe L, **Albertsen PC**, Litwin MS, Manyak MJ, O'Leary MP, Painter MR. Practice Trends in the Diagnosis and Management of Benign Prostatic Hyperplasia in the United States. *J Urol* 1995; 154:205-206.
25. Gee WF, Holtgrewe L, **Albertsen PC**, Litwin MS, Manyak MJ, O'Leary MP, Painter MR. Practice Trends in the Diagnosis and Management of Prostate Cancer in the United States. *J Urol* 1995; 154:207-208.
26. **Albertsen PC\***, Fryback DG, Storer BE, Kolon TF, Fine J. The Impact of Co-morbidity on Life Expectancy Among Men with Localized Prostate Cancer. *J Urol* 1996; 156:127-132.
27. **Albertsen PC\***. African-Americans and Prostate Cancer. *Cancer Journal from Scientific American* 1996; 2(4):2000.
28. Lu-Yao GL, Potosky AL, **Albertsen PC**, Wasson JH, Barry MJ, Wennberg JE. Followup Prostate Cancer Treatments After Radical Prostatectomy - a Population Based Study. *JNCI* 1996; 88:166-173.

29. Welch WG, **Albertsen PC**, Nease RF, Bubocz TA, Wasson JH. Estimating Treatment Benefits for the Elderly - the Effect of Competing Risks. *Ann Int Med* 1996; 124:577-584.
30. **Albertsen PC\***. (Editorial) Defining Clinically Significant Prostate Cancer: Pathologic Criteria vs. Outcomes Data. *JNCI* 1996; 88:1177-1178.
31. Gee WF, Holtgrewe L, **Albertsen PC**, Litwin MS, Manyak MJ, O'Leary MP, Painter MR, Blizzard RT, Fenninger RB, Emmons L. Practice Trends of American Urologists in the Treatment of Impotence, Incontinence and Infertility. *J Urol* 1996; 156:1778-1789.
32. Welch WG, **Albertsen PC**, Wasson JH. Assessing Competing Risks in Treating the Elderly. *Hosp Practice* 1996; 31:155-166
33. **Albertsen PC\***. Contempo 1996: Urology. *JAMA* 1996; 275: 1857-8.
34. **Albertsen PC\***. Understanding Managed Care Contracts: a Primer for Urologists. *AUA Update Series* 1996; 15:190-195.
35. **Albertsen PC\***. Screening for Prostate Cancer is neither Appropriate nor Cost-Effective. *Urologic Clinics of North America* 1996; 23(4):521-530.
36. **Albertsen PC\***, Aaronson NK, Muller NJ, Keller SD, Ware JE. Health Related Quality of Life among Patients with Metastatic Prostate Cancer. *Urology* 1997; 49:207-217.
37. **Albertsen PC\***. Urologic 'Nuisances': How to Work up and Relieve Men's Symptoms. *Geriatrics* 1997; 52:46-55.
38. **Albertsen PC\***. Unraveling the Epidemiology of Prostate Cancer. *J Urol* 1997; 157:2223.
39. Ferrer FA, Miller LJ, Ramez IA, Kurtzman SH, **Albertsen PC**, Laudone VP, Kreutzer DL. Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In situ and In vitro Expression of VEGF by Human Prostate Cancer Cells. *J Urol* 1997; 157:2329-2333
40. **Albertsen PC\***. Prostate Disease in Older Men: 1. Benign Hyperplasia. *Hospital Practice* 1997; 32:61-81.
41. **Albertsen PC\***. The Promise of Outcomes Research. *Contemporary Urology* 1997; 9(5):27-33.
42. **Albertsen PC\***. Contempo 1997:Urology. *JAMA* 1997; 277:1904-1905.
43. **Albertsen PC\***. Editorial Comment on Temporal Trends In Rates of Prostate Cancer: Declining Incidence of Advanced Disease, 1974-1994. *J Urol* 1997; 158:1430.
44. **Albertsen PC\***. Prostate Disease in Older Men: 2. Cancer. *Hospital Practice* 1997;32:159-181.
45. Onel E, Hammond C, Wasson JH, Berlin BB, Ely MG, Laudone VP, Tarantino AE, **Albertsen PC\***. An Assessment of the Feasibility and Impact of Shared Decision Making in Prostate Cancer. *Urology* 1998;51:63-66.
46. **Albertsen PC\***, Nease RF Jr., Potosky AL. Assessment of Patient Preferences Among Men with Prostate Cancer. *J Urol* 1998; 159: 158-163.
47. Ferrer FA, Miller LJ, Andrawis, RI, Kurtzman SH, **Albertsen PC**, Laudone PC, Kreutzer DL. Angiogenesis and Prostate Cancer: In Vivo and In Vitro Expression of Angiogenesis Factors by Prostate Cancer Cells. *Urology* 1998; 51:161-167.
48. Gee WF, Holtgrewe HL, **Albertsen PC**, Cooper TP, Fenninger RB, Litwin MS, Manyak MJ, Meyer JJ, Miles BJ, O'Leary MP, Painter MR, Rohner TH, Thomas R, Blizzard RT, Emmons L. Subspecialization, Recruitment and Retirement Trends of American Urologists. *J Urol* 1998; 159:509-511.
49. **Albertsen PC\***. Computer Modeling—What should we look for? *J Urol* 1998; 159:934.
50. **Albertsen PC\***. Outcomes Research: A Primer for Urologists. *AUA Update Series* 1998; 14:106-112.
51. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe LH, **Albertsen PC**, Roehborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia. *N Eng J Med* 1998; 338:557-563.
52. Richman AM, Mayne ST, Jekel JF, **Albertsen PC**. Image Analysis combined with Visual Cytology in the Early Detection of Recurrent Bladder Carcinoma. *Cancer* 1998; 82:1738-48.
53. **Albertsen PC\***, Hanley JA, Gleason DF, Barry MJ. A Competing Risk Analysis of Men Age 55-74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer. *JAMA* 1998; 280:975-980.
54. **Albertsen PC\*** Hanley JA, Murphy Setzko M. Statistical Considerations When Assessing Outcomes Following Treatment for Prostate Cancer. *J Urol* 1999; 162:439-444.
55. Lu-Yao GL, **Albertsen PC**, Warren J, Yao SL. Effect of Age and Surgical Approach on Complications and Short Term Mortality Following Radical Prostatectomy: A Population Based Study. *Urology* 1999; 54:301-307.
56. Seidenfeld J, Samson DJ, Aronson N, **Albertsen PC**, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. *Evidence Report: Technology Assessment (Summary)* 1999; (4):I-x, 1-246, II-36.
57. **Albertsen PC\***. Who Needs to Be Treated? *Molecular Urology* 1999; 3(3):183-190.

58. Fowler JF Jr, Collins MM, **Albertsen PC**, Zietman A, Elliott DB, Barry MJ. Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. *JAMA* 2000; 238:3217-3222.
59. **Albertsen PC**, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG for the PLESS Study Group. Economic Analysis of Finasteride: A Model Based Approach Using Data from the Proscar Long-term Efficacy and Safety Study. *Clinical Therapeutics* 1999; 21:1006-1024.
60. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, **Albertsen PC**, Kreutzer DL. Expression of Vascular Endothelial Growth Factor Receptors in Human Prostate. *Urology* 1999; 54:567-572.
61. Gilliland FD, Potosky AL, Harlan LC, **Albertsen PC**, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Predicting Extracapsular Extension of Prostate Cancer in Men Treated by Radical Prostatectomy: Results from the Population-based Prostate Cancer Outcomes Study. *J Urol* 1999; 162:1341-1345.
62. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, **Albertsen PC**, Eley JW, Liff M, Deapen D, Stephenson RA, Legler J, Gerrans CE, Talcott JA, Litwin MS. Commentary: Assessment of Prostate Cancer Practice Patterns and Quality of Life: The Prostate Cancer Outcomes Study. *JNCI* 1999; 91:1719-1724.
63. **Albertsen PC\*** Walters S, Hanley JA. A Comparison of Cause of Death Determination Among Men Previously Diagnosed with Prostate Cancer and Dying in Either 1985 or 1995. *J Urol* 2000; 163:519-523.
64. Sanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, **Albertsen PC**, Harlan LC, Potosky AL. Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer: The Prostate Cancer Outcomes Study. *JAMA* 2000; 283:354-360.
65. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, **Albertsen PC**, Bennett CL, Wilt TJ. Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer: A Systematic Review and Meta-analysis. *Ann Int Med* 2000; 132:566-577.
66. **Albertsen PC\***. Editorial Comment. *J Urol* 2000, 163:812.
67. **Albertsen PC\***. The Significance of Histology in Predicting the Natural History of Prostate Cancer. *Prostate J* 2000; 2:1-5.
68. McNaughton –Collins M, Fowler FJ Jr., Elliott DB, **Albertsen PC**, Barry MJ. Diagnosing and Treating Chronic Prostatitis: Do Urologists Use the Four-Glass Test? *Urology* 2000; 55:403-407.
69. **Albertsen PC\***, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA. Positive Yield of Imaging Studies in the Evaluation of Men with Newly Diagnosed Prostate Cancer: A Population-based Analysis. *J Urol* 2000; 163:1138-1143.
70. **Albertsen PC\***. When is Death from Prostate Cancer Not a Death from Prostate Cancer? *JNCI* 2000; 92(8):590.
71. Fowler FJ, McNaughton-Collins M, **Albertsen PC**, Zeitman A, Elliott DB, Barry MJ. Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. *JAMA* 2000; 283:3217-3222.
72. Potosky AL, Legler J, **Albertsen PC**, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health Outcomes After Radical Prostatectomy or Radiotherapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study (PCOS). *JNCI* 2000; 92(1):582-1592.
73. Gomella LG, **Albertsen PC**, Benson MC, Forman JD, Soloway MS. The Use of Video-based Patient Education for Shared Decision-making in the Treatment of Prostate Cancer. *Seminars in Urologic Oncology* 2000; 18(3): 182-187.
74. **Albertsen PC\***. The Natural History of Prostate Cancer. *Primary Care & Cancer* 2000; 20:8;18-25.
75. D'Alessandri RM, **Albertsen PC**, Atkinson BF, Dickler RM, Jones RF, Kirch DG, Longnecker DE, McAnamy ER, Parisi VM, Selby SE, Stapczynski S, Thompson JA, Wasserman AG, Zuza KL. Measuring Contributions to the Clinical Mission of Medical Schools and Teaching Hospitals. *Academic Medicine* 2000; 75:1231-1237.
76. Sneeuw KCA, **Albertsen PC**, Aaronson NK. Comparison of Patient and Spouse Assessments of Health Related Quality of Life in Men with Metastatic Prostate Cancer. *J Urol* 2001; 165, 478-482.
77. **Albertsen PC\***. Comparison of Recommendations by Urologist and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. *J Urol* 2001; 165(2): 731-731.
78. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, **Albertsen PC**, Hamilton AS, Hunt WC, Potosky AL. Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study. *JNCI* 2001; 93(5):388-95
79. Barry MJ, **Albertsen PC**, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobson SJ. Outcomes for Men with Clinically Nonmetastatic Prostate Carcinoma Managed with Radical Prostatectomy, External Beam Radiotherapy, or Expectant Management: A Retrospective Analysis. *Cancer* 2001; 91(12): 2302-14.

80. Hamilton AS, Stanford JL, Gilliland FD, **Albertsen PC**, Stephenson RA, Hoffman RM, Eley JAW, Potosky AL. Health Outcomes after External-Beam Radiation Therapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. *J Clinical Oncology*, 2001; 19(9): 2517-2526.
81. Potosky AL, Knopf K, Clegg LX, **Albertsen PC**, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality of Life Outcomes Following Primary Androgen Deprivation Therapy: Results from the Prostate Cancer Outcomes Study. *J Clinical Oncology* 2001; 19(17): 3750-3757.
82. Penson DF, **Albertsen PC**, Nelson PS, Barry M, Stanford JL. Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid? *JNCI* 2001; 93(23): 1822-1823
83. Harlan LC, Potosky AL, Gilliland FD, Hoffman R, **Albertsen PC**, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors Associated with Initial Therapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. *JNCI* 2001; 93(24): 1864-1871.
84. Samson D, Seidenfeld J, Wilt T, Schmitt B, **Albertsen PC**. Systematic Review and Meta-Analysis of Monotherapy Compared with Combined Androgen Blockage for Advanced Prostate Cancer. *Cancer* 2002; 95(2): 361-376.
85. **Albertsen PC\***. Which Results Justify the Means in Prostate Cancer Treatment? *Cancer Journal* 2002; 8(1):30-32.
86. Miller LJ, Fischer KA, Goralnick SJ, Litt M, Bursleson JA, **Albertsen PC**, Kreutzer DL. Interleukin-10 Levels in Seminal Plasma: Implications for Chronic Prostatitis-Chronic Pain Syndrome. *J Urol* 2002; 167(2): 753-756.
87. Collins S, Upshaw J, Rutchik S, Ohannessian C, Ortenberg J, **Albertsen PC**. Effects of Circumcision on Male Sexual Function: Debunking a Myth? *J Urol* 2002; 167(5): 2111-2112.
88. Schwartz E, **Albertsen P**. Nomograms for clinically localized disease. Part III: Watchful Waiting. *Seminars in Urologic Oncology* 2002; 20:140-145.
89. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, **Albertsen PC**, Gilliland FD, Stanford JL. Quality of Life Following Localized Prostate Cancer Treated Initially with Androgen Deprivation Therapy or No Therapy. *JNCI* 2002; 94(6): 430-7.
90. Miller LJ, Fischer KA, Goralnick SJ, Litt M, Bursleson JA, **Albertsen P**, Kreutzer DL. Nerve Growth Factor and Chronic Prostatitis/Chronic Pelvic Pain Syndrome. *Urology* 2002. 59(4):603-8
91. Taxel P, Fall PM, **Albertsen PC**, Dowsett RD, Trahiotis M, Zimmerman J, Ohannessian C, Raisz LG. The Effect of Micronized Estradiol on Bone Turnover and Calcitrophic Hormones in Older Men Receiving Hormonal Suppression Therapy for Prostate Cancer. *J Clinical Endocrinology and Metabolism* 2002; 87(11): 4907-13
92. Penson DF, **Albertsen PC**. Lessons Learnt About Early Prostate Cancer From Large Scale Databases: Population-based Pearls of Wisdom. *Surgical Oncology* 2002; 11:3-11.
93. Lu-Yao G, **Albertsen PC**, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural Experiment Examining Impact of Aggressive Screening and Treatment on Prostate Cancer Mortality in Two fixed Cohorts from Seattle area and Connecticut. *BMJ* 2002; 325(7367): 740. PMID: PMC128373
94. McNaughton-Collins M, Barry MJ, Zietman A, **Albertsen PC**, Talcott JA, Walker-Corkery E, Elliott DB, Fowler, FJ. United States Radiation Oncologists' and Urologist' Opinions about Screening and Treatment of Prostate Cancer vary by Region. *Urology* 2002; 60(4): 628-33.
95. **Albertsen PC\***. The conundrum of prostate cancer. *The Ca J* 2002; 8:432-434.
96. Kessler B, **Albertsen PC**. The natural history of prostate cancer. *Urol Clinics N Am* 30 (2003) 219-226.
97. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, **Albertsen PC**. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. *Cancer Immunology, Immunotherapy* 2003; 52:497-505.
98. Zeliadt SB, Penson DF, **Albertsen PC**, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. *Cancer* 2003; 98:496-503
99. **Albertsen PC\***. The prostate cancer conundrum. *JNCI* 2003; 95:930-931.
100. Hsieh K, Taylor JA, **Albertsen PC**. Lower Urinary Tract Symptoms in the Older Male. *Connecticut Medicine* 2003; 67(8): 487-90.
101. Penson DF, Feng Z, Kuniyaki A, McClerran D, **Albertsen PC**, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General Quality of Life two years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. *J Clin Oncology* 2003; 21:1147-1154.
102. Hsieh K, **Albertsen PC**. Populations at high risk for prostate cancer. *Urol Clinics N Am* 2003; 30:699-676.
103. **Albertsen PC\***, Hanley JA, Penson DF, Fine J. Validation of Increasing Prostate Specific Antigen as a Predictor of Prostate Cancer Death After Treatment of Localized Prostate Cancer with Surgery or Radiation. *J Urol* 2004:171:2221-2225.
104. Taylor JA 3rd, Kao TC, **Albertsen PC**, Shabsigh R. Bicycle Riding and its Relationship to the Development of Erectile Dysfunction. *J Urol* 2004; 172(3):1028-31.



105. Johnson, TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, **Albertsen PC**, Hamilton AS. Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer. *J Clin Oncology* 2004; 22(20):4193-4201
106. **Albertsen P\***. Editorial Comment on Does the Effectiveness of Bicalutamide in Reducing the Risk of Prostate Cancer Progression Vary with Lymph Node Status? *Nature Clinical Practice Urology* 2004; 1(1): 3
107. **Albertsen PC\***. Is Screening for Prostate Cancer with Prostate Specific Antigen an Appropriate Public Health Measure? *Acta Oncologica* 2005. 44(3):255-264.
108. **Albertsen PC\***. Prostate-Specific Antigen: How to Advise Patients as the Screening Debate Continues. *Cleveland Clinic Journal of Medicine* 2005; 72 (6):521-527.
109. **Albertsen PC\***, Hanley JA, Fine J. Twenty Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. *JAMA* 2005; 293: 2095-2101.
110. Penson DF, McLerran D, Feng Z, Li L, **Albertsen PC**, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-Year Urinary and Sexual Outcomes after Radical Prostatectomy: Results from the Prostate Cancer Outcomes Study. *J Urol* 2005; 173(5): 1701-5.
111. **Albertsen PC\***, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J. Prostate Cancer and the Will Rogers Phenomenon. *JNCI* 2005; 97(17):1248-1253.
112. **Albertsen PC\***. What is the Value of Screening for Prostate Cancer in the US? *Nature Clinical Practice Oncology* 2005;2(11):2-3.
113. **Albertsen PC\***. PSA Testing: Public Policy or Private Pendant?. *JAMA*. 2006;296(19):2371-2373.
114. **Albertsen PC\***. PSA and the Conservative Treatment of Early Prostate Cancer. *Arch Ital Urol Androl* 2006 Dec;78(4):152-3.
115. **Albertsen PC\***, Hanley JA, Penson DF, Barrows G, Fine J. Thirteen Year Outcomes following Treatment for Clinically Localized Prostate Cancer in a Population-based Cohort. *J Urol* 2007;177:932-936.
116. **Albertsen PC\***. Commentary: Occult Prostate Cancer -- Imposter or the Real Deal? *Intl Jrl of Epidemiology* 2007 36:281-282.
117. **Albertsen PC\***. Commentary on: Does radical prostatectomy provide a survival benefit as primary treatment for high-grade prostate cancer? *Nature Clinical Practice Urology* 2007; 4(2): 68-69 (2007).
118. **Albertsen PC\***. What do we really know about prostate cancer?. *Eur Urol* 2007; Oct;52(4):948-50..
119. Judge A, Evans S, Gunnell DJ, **Albertsen PC**, Verne J, Martin RM. Patient Outcomes and Length of Hospital Stay after Radical Prostatectomy for Prostate Cancer: analysis of Hospital Episodes Statistics for England. *BJU Intl* 2007. Nov;100(5):1040-9.
120. Seidenfeld J, Samson DJ, **Albertsen PC**. Competing Risks for Patients with Localized Prostate Cancer. *JNCI* 2007; 99(20):1498-1499.
121. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, **Albertsen P**, Verne J, Stephens P, Trotter C, Martin RM. Secular Trends in Prostate Cancer Mortality, Incidence and Treatment: England and Wales 1975-2004. *BJU Intl* 2008 Mar;101(5):547-555. PMID: PMC2765909
122. **Albertsen PC\***. Predicting Survival for Men with Clinically Localized Prostate Cancer: what do we need in contemporary practice? *Cancer* 2008 Jan 1;112(1):1-3.
123. Bellera C, Hanley JA, Joseph L, **Albertsen PC**. Hierarchical Change-point models for Biochemical Markers Illustrated by Tracking Post-Radiotherapy PSA Series in Men with Prostate Cancer. *Ann Epidemiol* 2008 Apr;18(4):270-82.
124. Bellera C, Hanley JA, Joseph L, **Albertsen PC**. Detecting Trends in Noisy Data Series: Application to Biomarker Series. *Am J Epidemiol* 2008 May 1;167(9):1130-9.
125. **Albertsen P\***. Should Men over the Age of 65 Years Receive PSA Screening? Argument Against. *Nature Clinical Practice Urology* 2008; 5(5):232-3.
126. **Albertsen PC\***. The Face of High Risk Prostate Cancer. *World J Urol* 2008 June; 26(3):205-10.
127. Dall'era MA, Cooperberg MR, Chan JM, Davies BJ, **Albertsen PC**, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active Surveillance for Early-Stage Prostate Cancer: review of the current literature. *Cancer* 2008 Apr 15;112(8):1650-1659.
128. **Albertsen P\***. Should Patients Consider Active Surveillance? *Cancer* 2008 Jun 15;112(12):2631-2634.
129. Collin SM, Martin RM, Metcalfe C, Gunnell D, **Albertsen PC**, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Prostate-cancer Mortality in the USA and UK in 1975-2004: an ecological study. *Lancet Oncol* 2008 May;9(5):445-52. PMID: PMC2760747
130. **Albertsen P\***. Should Men with Low-risk, Localized Prostate Cancer choose Active Surveillance or Undergo a Robotic Prostatectomy? *Curr Urol Rep* 2008 Jan;9(1):1-2.

131. Penson DF, McLerran D, Feng Z, Li L, **Albertsen PC**, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-Year Urinary and Sexual Outcomes after Radical Prostatectomy: results from the Prostate Cancer Outcomes Study. *J Urol* 2008 May;179(5 Suppl):S40-4.
132. Ercole B, Marietti SR, Fine J, **Albertsen PC\***. Outcomes Following Active Surveillance of Men with Localized Prostate Cancer Diagnosed in the PSA Era. *J Urol* 2008 Oct;180(4):1336-1339.
133. Lu-Yao GL, **Albertsen PC**, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Survival Following Primary Androgen Deprivation Therapy Among Men with Localized Prostate Cancer. *JAMA* 2008;300(2):173-181. PMID: PMC2645653
134. Kakizoe T, Mucci LA, **Albertsen PC**, Droller MJ. Screening for Bladder Cancer: Theoretical and Practical Issues in Considering the Treated and Untreated Natural History of the Various Forms of the Disease. *Scandinavian Jrl of Urol and Nephrology* 2008; 42 (suppl 218):191-212.
135. Lu-Yao GL, **Albertsen PC**, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, Treatment and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up. *J Gen Int Med* 2008 Nov;23(11):1809-14. PMID: PMC2585661
136. **Albertsen PC\***. The Treatment Paradigm Shifts Again on Prostate Cancer. *Eur Urol* 2009;55:9-11.
137. Kramer BS, Hagerty KL, Justman S, Somerfield MR, **Albertsen PC**, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *J Clin Oncol* 2009 Mar 20;27(9): 1502-1516.
138. **Albertsen PC\***. A Challenge to Contemporary Management of Prostate Cancer. *Nat Clin Pract Urol* 2009; Jan;6(1):12-13.
139. **Albertsen PC\***. Words of Wisdom. *Eur Urol* 2009 Apr;55(4):989-990.
140. Bellera C, Hanley JA, Joseph L, **Albertsen PC**. A Statistical Evaluation of Rules for Biochemical Failure following Radiotherapy in Men Treated for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2009;75(5):1357-1363.
141. Kramer BS, Hagerty KL, Justman S, Somerfield MR, **Albertsen PC**, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *J Urol* 2009 Apr;181(4):1642-1657.
142. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, **Albertsen P**, Costa J, Cordon-Cardo C. Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. *J Urol* 2009 Jul;182(1):125-132.
143. Roehrborn CG, **Albertsen P**, Stokes ME, Black L, Benedict A. First-year Costs of Treating Prostate Cancer: estimates from SEER-Medicare data. *Prostate Cancer Prostatic Dis* 2009;12(4), 355-60.
144. **Albertsen P\***. Androgen Deprivation in Prostate Cancer – Step by Step. *N Engl J Med* 2009 Jun 11;360(24)2572-4.
145. **Albertsen PC\***. The Unintended Burden of Increased Prostate Cancer Detection Associated with Prostate Cancer Screening and Diagnosis. *Urology* 2010 Feb;75(2):399-405.
146. **Albertsen P\***. Lies, Damn Lies, and Cancer Statistics. *Eur Urol* 56 (2009)592-593.
147. Welch HG, **Albertsen PC**. Prostate Cancer Diagnosis and Treatment after the Introduction of Prostate-Specific Antigen Screening: 1986-2005. *JNCI* 2009; Oct 7;101(19):1325-9.
148. **Albertsen PC\***. An Iatrogenic Confounding Variable. *JNCI* 2009 Oct. 21;101(20):1368-9
149. Delbanco T, **Albertsen PC**. A 72-Year Old Man with Localized Prostate Cancer – 14 Years Later. *JAMA* 2009 Sep 9;302(10):1105-6.
150. **Albertsen PC\***. Regionalizing Urologic Cancer Care: Appropriate Health Care Policy? *Urologic Oncology: Seminars and Original Investigations* 2010; (28):1-3.
151. Bailey DE, Wallace M, Latini DM, Hegarty J, Carroll PR, Klein EA, **Albertsen PC**. Measuring Illness Uncertainty in Men Undergoing Active Surveillance for Prostate Cancer. *Jrl of App Nurs Res* 24 (2011 Nov);193–199.
152. Lu-Yao GL, **Albertsen PC**, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker-Corkery E, Yao S-L. Outcomes of Localized Prostate Cancer Following Conservative Management. *JAMA* 2009 Sep 16;302(11):1202-9. PMID: PMC2822438
153. Greene KL, **Albertsen PC**, Babaian RJ, Carter HB, Gann PH, Han M, Kuban D, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate Specific Antigen Best Practice Statement: 2009 Update. *J Urol* 2009 Nov;182(5):2232-41.
154. **Albertsen PC\***. Does the Benefit Justify the Risk? *JNCI* 2010;102(1):1-2.

155. Shao YH, **Albertsen PC**, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL. Risk Profiles and Treatment Patterns among Men Diagnosed as having Prostate Cancer and a Prostate Specific Antigen Level Below 4.0 ng/ml. *Arch Intern Med* 2010 Jul 26;170(14):1256-61.
156. **Albertsen PC\***. Efficacy versus Effectiveness in Prostate-Specific Antigen Screening. *JNCI* 2010;102(5):288-289.
157. Stokes ME, Black L, Benedict A, Roehrborn CG, **Albertsen P**. Long-Term Medical-Care Costs Related to Prostate Cancer: Estimates from Linked SEER-Medicare Data. *Prostate Cancer Prostatic Dis* 2010 Sept;13(3):278-284.
158. Hamilton AS, **Albertsen PC**, Johnson TK, Hoffman R, Morrell D, Deapen D, Penson DF. Trends in Treatment of Localized Prostate Cancer using Supplemented Cancer Registry Data. *BJU Int* 2011 Feb;107(4):576-584.
159. **Albertsen PC\***. Treatment of Localized Prostate Cancer: When is Active Surveillance Appropriate? *Nat Rev Clin Oncol* 2010 Jul;7(7):394-400.
160. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, **Albertsen P**. Risedronate Prevents Early Bone Loss and Increased Bone Turnover in the First 6 Months of Luteinizing Hormone-Releasing Hormone-Agonist Therapy for Prostate Cancer. *BJU Intl* 2010 Nov;106(10):1473-6.
161. **Albertsen PC\***. When is Active Surveillance the Appropriate Treatment for Prostate Cancer? *Acta Oncologica* 2011, 50 (Suppl 1):120-126.
162. **Albertsen PC\***. Further Support for Active Surveillance in the Management of Low-Volume, Low-Grade Prostate Cancer. *Eur Urol*. 2010 Dec;58(6):836-7.
163. Thong MSY, van de Poll-Franse L, Hoffman RM, **Albertsen PC**, Hamilton AS, Stanford JL, Penson DF. Diabetes Mellitus and Health-Related Quality of Life in Prostate Cancer: 5-Year Results from the Prostate Cancer Outcomes Study. *BJU Int* 2010 Nov 11;107(8):1223-1231.
164. **Albertsen PC\***. WHO International Consultation on Prostate Cancer: A Summary. *Acta Oncol*. 2011 Jun;50 Suppl 1:155-60
165. Gjertson CK, **Albertsen PC**. Use and Assessment of PSA in Prostate Cancer. *Med Clin North Am* 2011 Jan;95(1):191-200.
166. **Albertsen PC\***. Active Surveillance Compared with Initial Treatment in Men with Low-Risk Prostate Cancer: a decision analysis. *Eur Urol* 2011 May;59(5):882-3.
167. **Albertsen PC\***, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. *J Clin Oncol*. 2011 Apr 1;29(10):1335-41.
168. Roberts CB, **Albertsen PC**, Shao YH, Moore DF, Mehta AR, Stein MN, Lu-Yao GL. Patterns and Correlates of Prostate Cancer Treatment in Older Men. *Am J Med* 2011 Mar;124(3):235-243.
169. **Albertsen PC\***. The Timing and Extent of Androgen Ablative Therapy for Prostate Cancer: Weighing the Clinical Evidence. *Endocrinol Metab Clin N Am* 2011 In press.
170. Shao Y-H, **Albertsen PC**, Shih W, Roberts CB, Lu-Yao GL. The Impact of PSA Testing Frequency on Prostate Cancer Incidence and Treatment in Older Men. *Prostate Cancer Prostatic Dis* 2011 Dec;14(4):332-9.
171. Ginzburg S, **Albertsen PC**. The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence. *Endocrinol Metab Clin North Am*. 2011 Sep;40(3):615-23.
172. Catto JW, Robinson MC, **Albertsen PC**, Goepel JR, Abbod MF, Linkens DA, Davis M, Rosario DJ, Warren AY, Varma M, Griffiths DF, Grigor KM, Mayer NJ, Oxley JD, Deshmukh NS, Lane JA, Metcalfe C, Donovan JL, Neal DE, Hamdy FC. Suitability of PSA-detected Localised Prostate Cancers for Focal Therapy: Experience from the ProtecT Study. *Br J Cancer* 2011 Sept 27;105(7):931-7
173. **Albertsen P**. A Tale of 2 Perspectives: The Clinician and the Public Health Professional. *Cancer* 2011 Oct 17.
174. Bourke L, Chico TJA, **Albertsen PC**, Hamdy FC, Rosario DJ. Cardiovascular Risk in Androgen Suppression: Underappreciated Under-researched and Unresolved. *Heart* 2011 Dec 7.
175. Makarov DV, Desai RA, Yu JB, Sharma R, Abraham N, **Albertsen PC**, Penson DF, Gross CP. The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. *J Urol* 2012 Jan;187(1) :97-102.
176. Bourke L, Chico TJ, **Albertsen PC**, Hamdy FC, Rosario DJ. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. *Heart*. 2012 Mar, 98(5):345-8. PMID: 22155645.
177. Zhu X, **Albertsen PC**, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ. Risk-Based Prostate Cancer Screening. *Eur Urol*. 2012 Apr; 61(4):652-61.
178. Makarov DV, Desai R, Yu JB, Sharma R, Abraham N, **Albertsen PC**, Krumholz HM, Penson DF, Gross CP. Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. *Health Aff (Millwood)*. 2012 Apr;31(4):730-40 PMID: 22492890
179. **Albertsen PC**. How best to use our tools? *Eur Urol*. 2012 Aug;62(6):201-2. PMID: 22386191

180. **Albertsen PC.** Robot-assisted radical prostatectomy – fake innovation or the real deal? *Eur Urol.* 2012 Sep;62(3):365-7. PMID:22705383
181. Lu-Yao GL, **Albertsen PC**, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. *Eur Urol.* 2012 Dec;62(6):966-72. PMID: 22608160
182. **Albertsen PC.** What is the Risk Posed by Prostate Cancer? *JNCI Monographs* 2012 Dec:2012(45):169-174.
183. Greene KL, **Albertsen PC**, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; erican Urological Association. *J Urol.* 2013 Jan; 189(1Suppl): S2-S11. PMID 23234625
184. Resnick MJ, Koyama T, Fan KH. **Albertsen PC**, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. *N Engl J Med.* 2013 Jan 31; 368(5):436-45. PMID: 23363497
185. Struder UE. **Albertsen PC.** It's time to change the treatment paradigm for prostate cancer! *Eur Urol.* 2013 Jan;63(1):97-9. Discussion 99-100. PMID: 22959353
186. Van den Bergh RC, **Albertsen PC**, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG. Timing of Curative Treatment for Prostate Cancer: A Systematic Review. *Eur Urol.* 2013 Feb 22. PMID:23453419
187. Noon AP, **Albertsen PC**, Thomas F, Rosario DJ, Catto JW. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. *BR J Cancer.* 2013 Mar 12. PMID: 23481180

#### INVITED ARTICLES:

1. **Albertsen PC\***. Rising Health Care Costs: Who's to Blame? *Hartford Courant*, September 23, 1990.
2. **Albertsen PC\***. The Medicare Pie: How will it be Sliced? *AUA Today*, October 1990.
3. **Albertsen PC\***. Health Care in America: Where are We Going? *AUA Today*, March 1991.
4. **Albertsen PC\***. Prospective Payment System: Rent Control for Health Care? *AUA Today*, October 1991.
5. **Albertsen PC\***. Fracchia J. Alternative to Recertification Needed. *AUA Today*, April 1992.
6. **Albertsen PC\***. Urologist Expresses Views on Recertification. *Clinical Urology Forum* 1992, 4:5.
7. **Albertsen PC\***. Decision Making in Urology. *1995 Monographs in Urology* 1995, 16:69-82.
8. Naitoh J, **Albertsen PC.\*** Current Concepts in Prostate Cancer Screening. *Cortlandt Forum*, June, 1996.
9. **Albertsen PC\***, Baum N. Nine Strategies for Making Your Urology Practice Managed Care-Friendly. *Cont Urol.* 8(12):13-27, 1996.
10. Onel E, **Albertsen PC\***. Management of Impotence. *Cortlandt Forum* 1997, 10:271-274.
11. Murphy-Setzko M., **Albertsen PC\***. Persistently Recurring Urinary Tract Infection. *Cortlandt Forum* January, 1997.
12. Kolon TF, **Albertsen PC\***. Diagnosis and Treatment of Scrotal Abnormalities. *Cortlandt Forum* 1997; 10:210-221.
13. **Albertsen PC\***. The Dilemma over PSA Screening. *Cortlandt Forum* 2001, 14:80.
14. **Albertsen PC\***. The Role of PSA Screening in Early Detection of Prostate Cancer. *Principles and Practice of Oncology, Updates*, 2001;15:1-16.

#### BOOK CHAPTERS

1. **Albertsen PC\***, Wasson JH, Barry MJ. Observation as a Treatment Option Among Men with Clinically Localized Prostate Cancer. *Current Clinical Oncology* 1994, 12:185-196.
2. **Albertsen PC\***. Early Stage Prostate Cancer: When is Observation Appropriate? *Hematology/Oncology Clinics of North America* 1996, 10:611-625.
3. **Albertsen PC\***. Screening for Prostate Cancer is Neither Appropriate Nor Cost Effective. *Urologic Clinics of North America.* 1996, 23:1-9.
4. **Albertsen PC\***. Decreasing Prostate Cancer Mortality in the USA. Is the Value of Screening Already Proven? *Renal, Bladder and Prostate Cancer: An Update.* Schröder FH Editor. The Parthanon Publishing Group: United Kingdom, 1999.
5. **Albertsen PC\***. A Current Synthesis of the Management of Prostate Cancer. When is observation appropriate? *Current Clinical Urology: Management of Prostate Cancer.* E.A. Klein, Ed. Totowa, NJ: Humana Press, Inc. 1999, pp. 103-116.
6. **Albertsen PC\***. Chapter 3: Prostate Cancer. *Classic Papers in Urology.* Oxford England: Isis Medical Media LTD, 1999, pp.45-65.
7. **Albertsen PC\***. Chapter 1: Epidemiology of Prostate Cancer: An Overview. *Advanced Therapy in Prostate Disease.* Resnick M and Thompson IA, Editors. Hamilton, Ontario: BC Decker, Inc. 2000, pp. 1-5
8. **Albertsen PC\***. Chapter 42A: Treatment of Early Stage Prostate Cancer - Expectant Management. *Comprehensive Textbook of Genitourinary Oncology.* Vogelzang N, Editors. Philadelphia, Lippincott, Williams & Wilkens, 2000.

9. **Albertsen PC\***. Chapter 61: Benign and Malignant Diseases of the Prostate. *Principles and Practices in Geriatric Surgery*. Rosenthal RA, Zenilman M, and Katlic M, Editors. Springer-Verlag, 2000, pp 806-816.
10. **Albertsen PC\*** Chapter 2: Natural History of Prostate Cancer. *Current Clinical Concepts: Prostate Cancer Screening*. Thompson IM, Resnick MI, Klein EA, Editors, Humana Press 2001.
11. **Albertsen PC\***. Chapter 13: Clinical Epidemiology: Incidence Rates, Databases, Age, and Co-Morbidity. *Prostate Cancer Principles & Practice*. Kantoff PW, Carroll PR, D'Amico AV, Editors. Ross RK, Isaacs JT, Scher HI, section editors. Lippincott, Williams & Wilkins, Philadelphia 2002, pp. 178-192.
12. Schroeder FH, **Albertsen PC**, Boyle P, Candas B, Catalona W, Cheng C, DeKonig HJ, Fourcade R, Hugosson J, Moul J, Perrin P, Roehrborn C, Rubben H, Stephenson R, Yamanaka H. Early detection and screening for prostate cancer. *Prostate Cancer*. Denis L, Bartsch G, Khoury S, Murai M, Partin A editors. Paris: Health Publication – 2003, 2003.
13. Fine J, **Albertsen PC\***. Chapter 3: Budget Development and Staffing. *Clinical Research Methods for Surgeons*. Wei JT, Penson DF editors. Humana Press 2006, pp. 47-60.
14. Marietti SR, **Albertsen PC**. Prostate Cancer Screening. *Therapeutic Strategies in Prostate Cancer*. Fenely and Payne 2007.
15. **Albertsen, PC\***. Chapter 1: Mortality Trends in Prostate Cancer. *Treatment Methods for Early and Advanced Prostate Cancer*. Kirby, RS, Partin AW, Parsons JK, Feneley MR Editors. Informa UK Ltd 2008, pp. 3-8.
16. **Albertsen, PC\***. Chapter 61: Screening for Prostate Cancer. *CANCER: Principles & Practice of Oncology, 9<sup>th</sup> ed.* DeVita V, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA editors. Lippincott Williams & Wilkins, Philadelphia. May 2011.

#### BOOK REVIEWS

1. **Albertsen PC\***. “Preventing Prostate cancer: Screening versus Chemoprevention.” *JNCI* 1995, 87:1714.
2. **Albertsen PC\***. “How I Survived Prostate Cancer... and so can You”. *JNCI* 1995, 87:1085.
3. **Albertsen PC\***. “Controversies in the Treatment of Prostate Cancer”, *N Engl J Med* 360(3):311-312, January 15, 2009.

#### LETTERS TO THE EDITOR

1. **Albertsen PC\***. A 72 year-old man with localized prostate cancer. *JAMA* 1995, 247:1426-27.
2. **Albertsen PC\***. Survival and conservative treatment for localized prostate cancer. *JAMA* 1996, 275:31.
3. Fryback DG, **Albertsen PC**, Storer BE. Prostatectomy and survival among men with clinically localized prostate cancer. *JAMA* 1996, 276:1723-24.
4. **Albertsen PC\***, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer *J Urol* 1997, 157:694-5.
5. **Albertsen PC\***, Quality of Life and Advanced Cancer”. *JNCI* 1999, 91:646.
6. Bellera CA, Hanley JA, Joseph L, **Albertsen PC**. A Charting Tool for Estimating the PSA Doubling Time in Patients with Prostate Cancer. *International Journal of Radiation Oncology\*Biophysics* 2006, 66(1).
7. **Albertsen PC\***. Reply to: PSA Screening and Elderly Men. *JAMA* 2007, 297(9):949-950
8. Lu-Yao G, Barry M, **Albertsen PC**, Yao SL. Outcomes of Treatment vs. Observation of Localized Prostate Cancer in Elderly Men. *JAMA* 2007, 297(15):1651.
9. Editorial Comment. **Albertsen PC**. *Urology*. 2012 Oct;80(4):888. PMID 22921701
10. **Albertsen PC**. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. *BJU Int*. 2012 Dec;110(11):1653. PMID: 2298489

\*corresponding author